Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Global Energy Roundup: Market Talk

Global Energy Roundup: Market Talk

Dow JonesDow Jones2026/09/04 04:37

The latest Market Talks covering Energy markets. Published exclusively on Dow Jones Newswires throughout the day.

0437 GMT - Doosan Enerbility appears well positioned to capture opportunities in new nuclear projects, with its order backlog steadily increasing, say Nomura's Cindy Park and Dongmin Lee. The analysts expect Doosan's nuclear power plant equipment order backlog to grow at an annual rate of 29% in 2026-2030 amid expanding global nuclear power capacity. The company's small modular reactor foundry business is expected to increase its annual production capacity to 20 by 2028 from 12 currently, supported by U.S. clients including NuScale Power and TerraPower, they say. Nomura resumes coverage of the stock with a buy rating and a target price of 110,000 won. Shares are last 0.4% lower at 78,900 won. (kwanwoo.jun@wsj.com)

(END) Dow Jones Newswires

September 04, 2026 00:37 ET (04:37 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.

智通财经2026/09/14 01:06
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas